Clinical trial · Observational
Physical Activity During Chemo- and/or Immunotherapy for Lung Cancer
Assessment of Physical Activity During Chemo- and/or Immunotherapy for Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this trial is to describe the pattern of physical activity in patients with non-small cell lung cancer during chemo- and/or immunotherapy, to evaluate potential predictors of those patterns and to assess potential correlations with patient reported outcomes (pain-, distress-, and fatigue scores). To reach this goal, this trial will be first trial in which the mean number of steps per week performed at baseline and during each week of chemo- and or immunotherapy will be collected in a standardized prospective way. The trial is exploratory in nature with the aim to generate scientific hypotheses to be investigated in future clinical trials.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (NSCLC) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with steps counted by their smart phone
- description
- The purpose is to obtain a patient's mean number of steps per week directly from the patient's smart phone which has a step counter.
Primary outcomes (1)
- measure
- Mean number of steps per week performed at baseline and during the first three cycles of chemo- and/or immunotherapy for lung cancer
- timeFrame
- through study completion, 9 weeks
- description
- The primary endpoint is to assess the mean number of steps per week during the first three cycles of chemo- and/or immunotherapy for lung cancer. The baseline value is represented by the mean number of steps during the last week prior to chemotherapy and/or immunotherapy. Any type of smart phone is allowed, as long as it has a step counter.
Secondary outcomes (3)
- measure
- Degree of the impact of pain on the mean number of steps per week asessed using the Numeric Pain Rating Scale
- timeFrame
- through study completion, 9 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically proven non-small cell lung cancer 2. Indication for chemo- and/or immunotherapy 3. Possession of and ability to use a smart phone that includes a step counter 4. Willingness to wear the smart phone close to the body at any time 5. Age ≥18 years 6. Written informed consent 7. Capacity of the patient to consent Exclusion Criteria: 1. Small-cell lung cancer 2. Karnofsky performance score \<60 3. Thoracic surgery within 3 months prior to chemo- and/or immunotherapy 4. Expected Non-Compliance
References
Publications (0)
Data not yet available